Trastuzumab deruxtecan (solution)|1826843-81-5|(DS-8201 (solution); DS-8201a (solution))-陌孚医药/Medlife

您当前的位置：

Trastuzumab deruxtecan (solution) (Synonyms: DS-8201 (solution); DS-8201a (solution))

目录号: PL03732 纯度: ≥99%

CAS No. :1826843-81-5

商品编号	规格	价格	会员价	是否有货	数量
PL03732-1mg(10mg/mL*100μLinAqueoussolution)	1mg(10mg/mL*100μLinAqueoussolution)	¥14144.00	请登录
PL03732-5mg(10mg/mL*500μLinAqueoussolution)	5mg(10mg/mL*500μLinAqueoussolution)	¥32145.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Trastuzumab deruxtecan (solution)
英文名称	Trastuzumab deruxtecan (solution)
英文别名	Trastuzumab deruxtecan;Trastuzumab deruxtecan (solution)
Cas No.	1826843-81-5
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Trastuzumab deruxtecan (DS-8201a) (solution) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。Trastuzumab deruxtecan (solution) 由人源化抗 HER2 抗体，酶促裂解的肽接头和拓扑异构酶 I 抑制剂组成。Trastuzumab deruxtecan (solution) 可用于 HER2 阳性乳腺癌和胃癌的研究。

生物活性

Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan (solution) is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan (solution) can be used for the research of HER2-positive breast cancer and gastric cancer.

性状

Liquid

体外研究(In Vitro)

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) (solution) inhibits the growth of HER2-positive KPL-4 cells, with an IC50 of 109.7 pM.
Trastuzumab deruxtecan (10 nM; 5 days) (solution) shows bystander killing effects in HER2-negative MDA-MB-468 cells. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay

体内研究(In Vivo)

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) (solution) shows antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition.
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) (solution) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.
[2]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation